hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06332820 id: 202401226RINB briefTitle: In Patients With Obstructive Airway Disease, Investigate the Effects of Different Breathing Strategies and Pedaling Rates on the Physiological Response to Bicycle Exercise overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-20 date: 2030-12-31 date: 2030-12-31 date: 2024-03-27 date: 2024-04-09 name: National Taiwan University Hospital class: OTHER briefSummary: The definition of obstructive airway disease is a ratio of the forced expiratory volume in one second (FEV1) to the forced vital capacity (FVC) of less than 0.7, which includes conditions such as chronic obstructive pulmonary disease, asthma, lymphangioleiomyomatosis, and bronchiolitis obliterans syndrome. For example, lung obstruction adversely affects many aspects of a patient's health, such as lung function and exercise capacity. Pulmonary rehabilitation is widely used in patients with obstructive airway disease, and the prescription of pulmonary rehabilitation depends on exercise capacity parameters such as peak oxygen uptake (peak VO2), peak workload, and anaerobic threshold. However, patients often have difficulty achieving training goals due to severe dyspnea during exercise. Dynamic hyperinflation is a common cause of dyspnea during exercise in patients with obstructive airway disease. Investigators aim to alleviate breathlessness by reducing dynamic hyperinflation, making it easier to achieve training goals. Methods to reduce dynamic hyperinflation include pursed lip breathing, reducing breathing rate to prolong expiratory time, using bronchodilators, and undergoing lung volume reduction surgery. Among these methods, reducing breathing rate to prolong expiratory time may be the most feasible, and investigators aim to change the rhythm and pace of breathing by adjusting the pedal rate of cycling exercise. The pedaling rate is typically set at 60 revolutions per minute. The European Respiratory Society recommended a pedal rate range of 40-70 revolutions per minute in 2019. There is still no consensus on the relationship between pedal rate and respiratory rate. This prospective observational study, using a crossover design, aims to investigate the effects of pedal rate during exercise testing on dynamic hyperinflation and exercise capacity in patients with obstructive airway disease. conditions: Obstructive Airway Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Inspiratory capacity during exercise measure: Change of FEV1 and symptoms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Taiwan University Hospital city: Taipei zip: 100 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06332807 id: NGGT002-P-2301 briefTitle: AAV Gene Therapy Clinical Study in Adult Classic PKU overallStatus: NOT_YET_RECRUITING date: 2024-05-22 date: 2030-12-30 date: 2030-12-30 date: 2024-03-27 date: 2024-03-27 name: NGGT (Suzhou) Biotechnology Co., Ltd. class: INDUSTRY briefSummary: This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene.
Participants will receive a single administration of NGGT002 and will be followed for safety and efficacy for 5 years. conditions: Phenylketonurias studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: NGGT002 measure: Incidence and severity of Adverse Events (AEs) measure: Change from baseline in clinical laboratory values measure: Change from baseline in 12-lead electrocardiograms (ECGs), vital signsand physical examinations measure: Change from baseline in Plasma Phe Concentration measure: Incidence of sustained plasma Phe concentration of ≤360 μmol/L at Week 12, Week 28, Week 52 and during Year 1 to 5 post dose measure: Change from baseline in total protein intake at at Week 28, Week 52 and during Year 1 to 5 post dose measure: Change in PKU Profile of Mood States (POMS) measure: Change in Phenylketonuria Quality of Life Questionnaire (PKU-QOL) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06332794 id: H-2201 briefTitle: Keep On Keep Up for Parkinson's acronym: KOKU4PD overallStatus: NOT_YET_RECRUITING date: 2024-06-03 date: 2025-03-01 date: 2025-06-30 date: 2024-03-27 date: 2024-04-24 name: Northumbria University class: OTHER name: University of Manchester name: Northumbria Healthcare NHS Foundation Trust name: Newcastle University name: Reason Digital briefSummary: The goal of this mixed methods, user research study is to evaluate the Keep On Keep Up programme for people with Parkinson's (KOKU4PD).
Participants will use the KOKU4PD app at home for 4 weeks. They will be assessed at baseline and after the 4 weeks to measure aspects of their disease status, mobility, thinking, mood and quality of life. They will also be asked to complete some questionnaires about the usability of the app. conditions: Parkinson's Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: KOKU4PD measure: Usability of the KOKU app measure: Executive clock drawing task (CLOX 1, 2) (mean Change from baseline) measure: Trail Making Test (mean Change from baseline) measure: Freezing of Gait Questionnaire (mean Change from baseline) measure: Falls Efficacy scale (mean Change from baseline) measure: Parkinson's disease quality of life questionnaire - PDQ-39 (mean Change from baseline) measure: Mini-BESTest (mean Change from baseline) measure: Two minute walk test, single and dual task (mean Change from baseline) measure: EuroQol-5 Dimension Quality of Life tool - EQ5D-5L (mean Change from baseline) measure: Activities-specific Balance Confidence (ABC) Scale (mean Change from baseline) measure: Multidimensional Fatigue Inventory (MFI) (mean Change from baseline) measure: Technology Acceptance questionnaire sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northumbria University city: Newcastle upon Tyne state: Tyne & Wear zip: NE1 8ST country: United Kingdom name: Gill Barry, PhD role: CONTACT phone: 01912277635 email: gill.barry@northumbria.ac.uk name: Julia Das role: CONTACT phone: 01912373343 email: julia.das@northumbria.ac.uk lat: 54.97328 lon: -1.61396 hasResults: False
nctId: NCT06332781 id: 2126175 briefTitle: Intravesical Gentamicin to Prevent Recurrent UTI overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2025-06-01 date: 2025-07-31 date: 2024-03-27 date: 2024-03-28 name: Women and Infants Hospital of Rhode Island class: OTHER briefSummary: Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI) conditions: Recurrent Uti studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 30 type: ESTIMATED name: Gentamicin name: Nitrofurantoin measure: UTIs measure: Patient reported outcome measures measure: Patient reported outcome measures measure: Patient reported outcome measures measure: Patient reported outcome measures measure: Patient reported outcome measures measure: Patient reported outcome measures measure: urobiome analysis measure: urobiome analysis sex: FEMALE minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332768 id: WEAN_2021 briefTitle: NIV Versus HFO Versus Standard Therapy Immediately After Weaning From Mechanical Ventilation in ARDS Patients overallStatus: COMPLETED date: 2017-09-01 date: 2022-01-01 date: 2022-03-01 date: 2024-03-27 date: 2024-03-27 name: Northern State Medical University class: OTHER briefSummary: The weaning failure is a paramount challenge when aggressive discontinuation of respiratory support in ARDS. The aim of the study is to improve weaning safety and efficacy by a transient postextubation non-invasive respiratory support. conditions: Mechanical Ventilation Complication conditions: Weaning Failure conditions: Acute Respiratory Distress Syndrome conditions: High-flow Oxygenation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized assignment primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ACTUAL name: Respiratory support measure: Weaning failure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City hospital # 1 city: Arkhangelsk state: Arkhangelsk Region zip: 163000 country: Russian Federation lat: 64.5401 lon: 40.5433 hasResults: False
nctId: NCT06332755 id: LG-LRCL001 briefTitle: Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors acronym: LB-LR1109 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-11 date: 2027-02 date: 2024-03-27 date: 2024-03-27 name: LG Chem class: INDUSTRY briefSummary: This is a Phase 1, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose(RP2D) of LB-LR1109 and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109, and its impact on quality of life in participants with unresectable and metastatic nonsmall cell lung cancer(NSCLC), head and neck squamous cell carcinoma(HNSCC), renal cell carcinoma(RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options. conditions: Non-small Cell Lung Cancer(NSCLC) conditions: Head and Neck Squamous Cell Carcinoma(HNSCC) conditions: Renal Cell Carcinoma(RCC) conditions: Urothelial Carcinoma conditions: Malignant Melanoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: LB-LR1109 measure: MTD and/or RP2D of LB-LR1109 in participants with advanced or metastatic solid tumors measure: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 measure: Preliminary efficacy of LB-LR1109 measure: Anti-tumor efficacy of LB-LR1109 measure: Pharmacokinetic profile of LB-LR1109 measure: Characterize PK of LB-LR1109 measure: Immunogenicity of LB-LR1109 measure: Quality of life of participants sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332742 id: QXZS for DOR briefTitle: Real-world Evaluation of Qingxin Zishen Decoction on Ovarian Reserve Function Clinical Efficacy in Patients With Decreased overallStatus: RECRUITING date: 2023-11-01 date: 2026-12-31 date: 2026-12-31 date: 2024-03-27 date: 2024-04-04 name: Yun Chen class: OTHER briefSummary: A prospective cohort study evaluated the clinical efficacy of Qingxin Zishen Decoction conditions: Decreased Ovarian Reserve studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 178 type: ESTIMATED measure: Traditional Chinese medicine syndrome score measure: serum sex hormone levels measure: serum AMH levels measure: transluminal ultrasound evaluation of ovarian antral follicles and other parameters (AFC) measure: Seven items of thyroid function measure: natural pregnancy rate sex: FEMALE minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: Jiangsu Provincial Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine status: RECRUITING city: Nanjing state: Jiangsu zip: 210023 country: China name: Chen Yun role: CONTACT phone: 8613675167221 email: 66teoyq@gmail.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06332729 id: EG,KFS,lab reserach 6 briefTitle: Universal Exercise Unit Versus Functional Electrical Stimulation On Genu Recurvatum In Diplegic Cerebral Palsy overallStatus: RECRUITING date: 2024-02-01 date: 2024-05-15 date: 2024-06-15 date: 2024-03-27 date: 2024-03-27 name: Mahmoud Reda Elsharkawy class: OTHER briefSummary: Summary:
The interventions in both groups aim to improve muscle strength, range of motion, and functional abilities in children with cerebral palsy. conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 32 type: ESTIMATED name: universal exercis unit name: functional electrical stimulation measure: muscle strength using muscle tester device measure: Range of motion using kinoviea software and digital goniometer measure: range of motion for the joint using digital geniometer sex: ALL minimumAge: 4 Years maximumAge: 8 Years stdAges: CHILD facility: Physical Therapy status: RECRUITING city: Kafr Ash Shaykh country: Egypt name: Mahmoud R Elsharkawy, bachelor role: CONTACT phone: 01021417889 email: mahmoud.elsharakawy1994@gmail.com lat: 31.11174 lon: 30.93991 hasResults: False
nctId: NCT06332716 id: KY20222234 briefTitle: Research on the Correlation Between Organoid Drug Sensitivity Testing and Precise Treatment of Gastrointestinal Tumors overallStatus: RECRUITING date: 2022-08-26 date: 2025-12 date: 2025-12 date: 2024-03-27 date: 2024-03-27 name: Jianjun Yang,MD class: OTHER briefSummary: Study the correlation between in vitro drug sensitivity screening of digestive tract tumor organoids and their clinical efficacy in anti-tumor treatment, evaluate the use of digestive tract tumor organoid drug sensitivity to predict the therapeutic effect of anti-tumor drugs, and explore new methods for personalized and precise treatment of esophageal cancer, gastric cancer, colorectal cancer, and gastrointestinal stromal tumors. conditions: Gastrointestinal Tumors，3D Organoids，Drug Sensitivity studyType: INTERVENTIONAL phases: PHASE3 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 68 type: ESTIMATED name: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. measure: Progression-free survival（PFS） measure: Overall survival（OS） sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: XijingH status: RECRUITING city: Xi'an state: Shaanxi country: China name: Jianjun Yang role: CONTACT phone: 13756154175 email: yangjj@fmmu.edu.cn lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06332703 id: IACA briefTitle: Acanthamoeba and Artificial Intelligence overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2025-04 date: 2024-03-27 date: 2024-03-27 name: IRCCS Ospedale San Raffaele class: OTHER briefSummary: Acanthamoeba keratitis, caused by the pathogen Acanthamoeba spp, is recognized worldwide as a severe ocular infection that can pose potential risks to vision.
The confocal images of this cohort will be fed into artificial intelligence software. To evaluate the model, the test set will be used, and the AI model's ability will be assessed using the most commonly used metrics in the field of computer vision such as accuracy, specificity, sensitivity, and f1-score; culminating in a comprehensive evaluation of the model. conditions: Acanthamoeba Keratitis conditions: Artificial Intelligence studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 151 type: ESTIMATED measure: Determination of the potential presence of significant patterns of Acanthamoeba infection in in-vivo confocal microscopy (IVCM) images. measure: Correlation assessment between IVCM images and laboratory results. sex: ALL minimumAge: 1 Year maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332690 id: 514.2021 briefTitle: OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO overallStatus: RECRUITING date: 2023-10-17 date: 2025-06 date: 2025-12 date: 2024-03-27 date: 2024-03-27 name: IRCCS Multimedica class: OTHER name: AbbVie briefSummary: The purpose of this pilot study is to evaluate different imaging parameters in patients with previously treatment-naive DME and ME due to RVO before and after treatment with dexamethasone implant, in order to find specific retinal inflammatory and microvascular biomarkers that may be predictive of treatment outcome. conditions: Diabetic Macular Edema conditions: Macular Edema Due to Diabetes Mellitus conditions: Retinal Vein Occlusion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: dexamethasone implant measure: Modification of inflammatory biomarkers on OCT and perfusion density parameters on OCT-A at 4 months after surgery (Change measure) measure: Initial clinical characteristics in patients with a gain in BCVA (Best Corrected Visual Acuity) of ≥ 5, ≥ 10, and ≥ 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MultiMedica IRCCS Multimedica status: RECRUITING city: Milan zip: 20123 country: Italy name: Stela Vujosevic, MD role: CONTACT phone: +39 02 85 99 4601 email: stela.vujosevic@multimedica.it name: GAbriele Piccoli role: CONTACT phone: +39 02 85 99 4601 email: gabriele.piccoli@multimedica.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06332677 id: TERS briefTitle: Target of Suv420h1/2 in Hepatocytes overallStatus: RECRUITING date: 2023-03-01 date: 2025-02 date: 2026-02 date: 2024-03-27 date: 2024-03-27 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: Nonalcoholic fatty liver disease (NAFLD) is globally the leading cause of liver disease and frequently progresses to cirrhosis and liver cancer. The identification of effective drugs is the main unmet clinical need. Changes in liver histones methylation accompanies the development and progression of NAFLD. Our preliminary data demonstrate that inactivation of the methyltransferases SUV420H1/2 in hepatocytes protects mice against NAFLD. In this project we propose to examine the relevance of these findings by evaluating the impact of genetic deletion of hepatic SUV420H1/2 in mice fed a steatogenic diet. To further evaluate the potential for clinical translation of these results, we will next 1) evaluate the expression of SUV420H1/2 in human liver transcriptomic data and 2) analyze the impact of genetic variations on disease outcomes in population-based cohorts; 3) test an innovative therapeutic approach based on hepatocyte-targeted antisense oligonucleotides downregulating SUV420H1/2 in human liver organoids/assembloids. conditions: NAFLD studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: study the cellular and molecular mechanisms of correlation between the SUV420H1/H2 methyltransferase and the progression of liver damage in mice (San Raffaele Institute) and to confirm these findings in human samples and in vitro 3D liver models. primaryPurpose: PREVENTION masking: NONE count: 260 type: ESTIMATED name: the main genes and expression by comparing the transcriptomic lipidomic profile measure: the main genes and expression by comparing the transcriptomic lipidomic profile measure: the main genes and expression by comparing the transcriptomic lipidomic profile sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica status: RECRUITING city: Milano zip: 20122 country: Italy name: Luca Vittorio Carlo Valenti role: CONTACT phone: 02 5503 6595 email: luca.valenti@policlinico.mi.it lat: 45.46427 lon: 9.18951 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-01-26 uploadDate: 2024-03-14T09:56 filename: Prot_SAP_000.pdf size: 703523 hasResults: False
nctId: NCT06332664 id: 2023-2330 briefTitle: Early Nutrition Intervention for M1 Stage Cancer Patients overallStatus: RECRUITING date: 2024-01-01 date: 2025-01-01 date: 2025-07-01 date: 2024-03-27 date: 2024-03-27 name: Xingchen Peng class: OTHER briefSummary: In China, the treatment of advanced-stage cancer often follows a pattern where the management of patients is primarily overseen by oncologists who focus on addressing the main clinical symptoms and intervening accordingly.
Against this background, the investigators integrated clinical nutritionists into the oncology treatment team and established a proactive nutritional intervention team specifically targeting M1 advanced-stage cancer patients. This initiative aims to conduct a single-center, open-label, randomized parallel-group prospective study, with the following objectives: 1) to evaluate the impact of this model on the nutritional status, survival, and quality of life of advanced-stage cancer patients, and 2) to further optimize this model for widespread replication in clinical practice. conditions: Nutrition conditions: Cancer Metastatic studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 194 type: ESTIMATED name: Early Nutrition Intervention measure: the incidence of cachexia measure: overall survival ；progression-free survival measure: Physical Fitness Status measure: BMI measure: Nutritional risk and malnutrition status measure: Patient's emotional changes measure: Caregiver psychological burden measure: Patient's physical, social, and cognitive functioning measure: incidence of Sarcopenia measure: Nutritional risk and malnutrition status measure: Patient's emotional changes sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West China Hospital, Sichuan Universit status: RECRUITING city: Chengdu state: Sichuan zip: 610041 country: China name: XingChen Peng, Ph.D role: CONTACT phone: +8618980606753 email: pxx2014@163.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06332651 id: NL84684.091.23 briefTitle: Metabolic Availability in Older and Younger Men acronym: YOMA overallStatus: RECRUITING date: 2024-02-19 date: 2024-12-31 date: 2025-04-01 date: 2024-03-27 date: 2024-03-27 name: Wageningen University class: OTHER briefSummary: The main goal of this study is to determine the metabolic availability of methionine in black beans, lysine in sorghum and lysine in milk using the indicator amino acid oxidation method both in older and in younger men. conditions: Ageing studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It is a parallel intervention study. The intervention does not involve a drug or biologic product, however does involve an adaptation diet and a diet with measured amino acids dissolved in water, during the test day. We investigate the amino acid metabolic availability using the IAAO method. primaryPurpose: PREVENTION masking: NONE count: 28 type: ESTIMATED name: Black beans name: Milk name: Sorghum measure: Metabolic availability of methionine in black beans and lysine in milk and sorghum measured with the indicator amino acid oxidation method. sex: MALE minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wageningen University & Research status: RECRUITING city: Wageningen state: Gelderland zip: 6708PB country: Netherlands name: Fenna Hinssen, MSc role: CONTACT phone: +031648043165 email: yoma@wur.nl name: Karen Fransen, MSc role: CONTACT phone: +031648043165 email: yoma@wur.nl lat: 51.97 lon: 5.66667 hasResults: False